

Reduced acquisition time PET pharmacokinetic modelling using simultaneous ASL–MRI: proof of concept

Journal of Cerebral Blood Flow & Metabolism
0(00) 1–14
© Author(s) 2018



Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/0271678X18797343
journals.sagepub.com/home/jcbfm



Catherine J Scott¹ , Jieqing Jiao¹, Andrew Melbourne¹,
Ninon Burgos^{1,2}, David M Cash^{1,3}, Enrico De Vita^{4,5,6},
Pawel J Markiewicz¹, Antoinette O'Connor³, David
L Thomas^{1,4,7}, Philip SJ Weston³, Jonathan M Schott³,
Brian F Hutton^{8,9} and Sébastien Ourselin¹⁰

Abstract

Pharmacokinetic modelling on dynamic positron emission tomography (PET) data is a quantitative technique. However, the long acquisition time is prohibitive for routine clinical use. Instead, the semi-quantitative standardised uptake value ratio (SUVR) from a shorter static acquisition is used, despite its sensitivity to blood flow confounding longitudinal analysis. A method has been proposed to reduce the dynamic acquisition time for quantification by incorporating cerebral blood flow (CBF) information from arterial spin labelling (ASL) magnetic resonance imaging (MRI) into the pharmacokinetic modelling. In this work, we optimise and validate this framework for a study of ageing and preclinical Alzheimer's disease. This methodology adapts the simplified reference tissue model (SRTM) for a reduced acquisition time (RT-SRTM) and is applied to [¹⁸F]-florbetapir PET data for amyloid- β quantification. Evaluation shows that the optimised RT-SRTM can achieve amyloid burden estimation from a 30-min PET/MR acquisition which is comparable with the gold standard SRTM applied to 60 min of PET data. Conversely, SUVR showed a significantly higher error and bias, and a statistically significant correlation with tracer delivery due to the influence of blood flow. The optimised RT-SRTM produced amyloid burden estimates which were uncorrelated with tracer delivery indicating its suitability for longitudinal studies.

Keywords

Positron emission tomography, arterial spin labelling, pharmacokinetic modelling, reduced acquisition time, cerebral blood flow

Received 30 November 2017; Revised 28 July 2018; Accepted 29 July 2018

¹Translational Imaging Group, CMIC, University College London, London, UK

²Inria, Aramis project-team, Institut du Cerveau et de la Moelle épinière, Inserm, CNRS, Sorbonne Université, Paris, France

³Dementia Research Centre, Institute of Neurology, University College London, London, UK

⁴Neuroradiological Academic Unit, UCL Institute of Neurology, London, UK

⁵Lysholm Department of Neuroradiology, National Hospital for Neurology and Neurosurgery, UCL Hospitals Foundation Trust, London, UK

⁶Department of Biomedical Engineering, School of Biomedical Engineering & Imaging Sciences, King's College London, King's Health Partners, St Thomas' Hospital, London, UK

⁷Leonard Wolfson Experimental Neurology Centre, UCL Institute of Neurology London, UK

⁸Institute of Nuclear Medicine, University College London, London, UK
⁹Centre for Medical Radiation Physics, University of Wollongong, NSW, Australia

¹⁰School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK

Corresponding author:

Catherine J Scott, Translational Imaging Group, University College London, 8th Floor MPEB, London WC1E 7JE, UK.
Email: catherine.scott.14@ucl.ac.uk

Introduction

Positron emission tomography (PET) facilitates the quantification of a range of important biomarkers through the injection and detection of targeted radiotracers. To interpret the measured signal and derive the biological parameters of interest, data are collected dynamically from injection, covering radiotracer delivery to tissue, interaction with the target, and tracer washout. This provides a map of the spatio-temporal concentration of the tracer *in vivo*. A pharmacokinetic model which describes these processes may then be fitted to these dynamic data to estimate the biological parameters such as radiotracer target density.

Depending on the radiotracer administered, the dynamic data acquisition time required to fit the model may be 60 min or more. This is prohibitive in a clinical context due to patient discomfort, restrictions on scanner time availability, and the increased chance of subject motion which corrupts the data. Consequently, a simplified technique is commonly employed.

The standardised uptake value ratio (SUVR) is a measure of relative tracer uptake which can be calculated from a static scan lasting approximately 10 min. SUVR is calculated by dividing the tracer concentration within the tissue of interest by the concentration in a reference region. The reference region consists of tissue considered to be free of the radiotracer target and represents the non-displaceable (*ND*) tracer concentration (i.e. tracer in the tissue which is not bound to the intended target). When the ratio of the tracer concentration within the target tissue and the reference tissue has reached a steady-state, SUVR approximates the distribution volume ratio (DVR). DVR can be estimated from pharmacokinetic modelling and is related to target density.

However, as SUVR is calculated from a single static scan, the tracer concentration present during the acquisition will depend on the delivery of the tracer, as well as target density. Tracer delivery is intrinsically linked to blood flow, and since blood flow can change during the progression of disease,¹ and indeed fluctuate over the course of a day,² SUVR estimates may be confounded.

The influence of cerebral blood flow (CBF) changes on SUVR estimates has been highlighted in longitudinal Alzheimer's disease studies in which the target of interest was the protein amyloid- β . Amyloid- β is an early indicator of disease onset and a therapeutic target, hence accurately quantifying amyloid- β density is of paramount importance. Here, variation in blood flow has been shown to cause spurious changes in SUVR which are unrelated to target density.^{3,4} Conversely, target density estimates derived from pharmacokinetic modelling of dynamic data starting from radiotracer injection can account for blood flow, as tracer delivery is parameterised within the model.

Dynamic PET data can be divided into two phases: the early phase, in which the signal is dominated by tracer delivery to tissue,⁵ and the late phase, which contains information related to tracer binding and washout, and is where SUVR is estimated. The intrinsic correlation between tracer delivery and CBF has been demonstrated for an amyloid- β tracer.⁶ Therefore, if CBF can be measured independently from the PET acquisition, then the data acquisition time may be reduced such that only the late phase data are acquired to estimate the remaining parameters.

Arterial spin labelling (ASL) magnetic resonance imaging (MRI) is a non-invasive imaging technique which applies a magnetic 'tag' to arterial blood, such that it can be used as an endogenous contrast agent. ASL can be used to estimate CBF, as validated by comparison with the gold standard radiolabelled water PET.⁷ While the accuracy of the technique is dependent on the implementation, high quantitative accuracy has been achieved when ASL data are normalised to a reference region.⁸

The introduction of combined PET/MRI scanners, which facilitate simultaneous acquisition, means that ASL and late phase PET data can be acquired concurrently. By incorporating CBF information from ASL into the PET pharmacokinetic modelling to provide early phase delivery information, the total acquisition time can be significantly reduced, increasing patient comfort and throughput, without sacrificing quantitative accuracy.

In this paper, we build on the framework which combines ASL-derived CBF data with PET kinetic modelling to reduce the acquisition time from 60 to 30 min.⁹ This is referred to here as the reduced acquisition time simplified reference tissue model (RT-SRTM). In the present work, the relationship between PET radiotracer delivery and ASL measured CBF is investigated with a larger group of subjects. An improved methodology for the estimation of the early phase data is proposed and compared to that used previously.⁹ Finally, the timing of the late phase acquisition is optimised before applying the improved methodology to a different set of subjects. This was applied to [¹⁸F]-florbetapir amyloid PET data from a study of ageing and preclinical Alzheimer's disease.

Material and methods

PET kinetic modelling

The simplified reference tissue model (SRTM)¹⁰ was used as the gold standard for PET pharmacokinetic modelling, as it is commonly applied in amyloid studies^{5,6,11,12} and has been validated against pharmacokinetic modelling with arterial sampling for [¹⁸F]-florbetapir.¹³ The

SRTM employs a reference region, which is considered to be devoid of the imaging target, to replace the plasma input function. Cerebellar grey matter was used as it is assumed to be devoid of amyloid- β .¹⁴

The operational equation between the tracer concentration in the target tissue $C_T(t)$ and the reference region $C_R(t)$ is formulated as shown in equation (1). Here t denotes time with tracer injection at $t = 0$, and \otimes represents the convolution operator

$$C_T(t) = R_1 C_R(t) + \left(k_2 - R_1 \frac{k_2}{1 + BP_{ND}} \right) C_R(t) \otimes e^{\frac{-k_2}{1 + BP_{ND}} t} \quad (1)$$

The SRTM contains three parameters: R_1 , which is the rate constant of tracer delivery to the target tissue relative to the reference tissue; k_2 , which is the rate constant from target tissue to blood; and the ND binding potential BP_{ND} , which is proportional to target density, i.e. the density of amyloid- β , see Supplementary Materials.

An in-house implementation of the SRTM using the basis function method¹⁵ was fitted to the PET data to derive regional gold standard parameter estimates, denoted by an asterisk, of BP_{ND}^* , k_2^* and R_1^* from dynamic PET data conventionally acquired for $t \in [0, 60]$ min, denoted here as $t = 0, 60$ min. For more details see Supplementary Materials.

PET kinetic modelling with reduced acquisition time

Early PET signal is dominated by the delivery of the tracer to the tissue and hence is important for the estimation of R_1 . The later part of the signal contains information about the binding of the tracer to the target and its subsequent washout, which is essential for the estimation of k_2 and BP_{ND} .

Consequently, if the blood flow information can be estimated independently from the PET data, then the acquisition time can be reduced, by recording only the late signal to allow the estimation of k_2 and BP_{ND} . This requires two modifications to the model: (i) the estimation of R_1 from another source, and (ii) extrapolation of the reference region curve, C_R to $t = 0$, as the model contains a convolution term which requires the full time series from injection to compute. Here, we refer to this modified model as the reduced acquisition time SRTM (RT-SRTM).

Derivation of PET- R_1 from ASL-CBF

R_1 is defined as $R_1 = K_1/K'_1$ where K_1 is the transfer rate constant from blood to target tissue and K'_1 is the transfer rate constant from blood to reference tissue. According to the Renkin-Crone^{16,17} capillary model,

the relationship between tracer delivery, K_1 , and blood flow, F , can be described as

$$K_1 = EF = \left(1 - e^{-\frac{PS}{F}} \right) F \quad (2)$$

The Renkin-Crone model includes a term for the net extraction of the tracer from the capillaries, E , which is dependent on the vessel permeability surface area product, PS . Under common physiological flow conditions, where PS/F is high (≥ 3), the relationship between K_1 and flow F is approximately linear. If we assume that PS is sufficiently high, the relationship between K_1 and F , and in turn the relationship between R_1 and F , can be approximated as a linear function,⁶ as expressed in equation (3)

$$R_1 = \frac{K_1}{K'_1} = \beta_0 + \beta_1 \frac{F}{F'} \quad (3)$$

ASL can be used to measure the CBF, F , and may be converted into an R_1 estimate to use in the RT-SRTM, using the relationship from equation (3), where F' indicates the CBF measured in the reference region.

In this study, linear regression between R_1 and CBF was performed in a group of subjects to determine whether this approximation is valid. The slope and intercept of the linear regression, β_0 and β_1 , can account for systematic differences between the modalities and an extraction fraction of $E < 100\%$. The derived β_0 and β_1 can then be applied to a different group of subjects to convert ASL-CBF to a derived R_1 value.

Due to systematic errors in ASL-CBF estimates in certain regions of the brain, particularly for single inversion time ASL data,⁷ multi-linear analysis was also performed, to determine whether β_0 and β_1 may be region dependent. Multi-linear regression has the capacity to model interaction terms between ASL-CBF and the region and can be described as in equation (4)

$$R_1 = \beta_0 + \beta_1 \frac{F}{F'} + \sum_{n=2}^{regions} \beta_n I[region_n] + \sum_{m=regions+1}^{2 \times regions} \beta_m \times \frac{F}{F'} \times I[region_m] \quad (4)$$

Here $I[region_n]$ is equal to 1 when $region_n$ is being considered, and 0 otherwise. Two further multi-linear analyses were also performed (i) using the subject as a covariate, and (ii) using both subject and regions as covariates to determine their relative influence on R_1 estimation.

Extrapolation of PET reference region, $C_R(t)$. To compute the convolution term in equation (1), C_R must be known from injection, at $t = 0$, to the end of the scan, $t = t_e$, where $t_s, t_e = 0, 60$ min for the gold standard. However, when reducing the acquisition time, C_R is only measured between t_s and t_e where $t_s \neq 0$, and therefore a strategy is required to extrapolate the missing data. Here we define $C_R(t)$ as a vector containing the reference region tracer concentration over time, $C_R^{pop}(t)$ as a matrix containing the reference region concentration for a population of subjects, and $\bar{C}_{R(t)}^{pop}$ as a vector containing the mean population tracer concentration. For clarity, the acquisition time, t , is expressed as a discrete variable, as the dynamic data are binned into frames.

In this work, two different approaches are evaluated to estimate the whole reference input vector $C_R[t = 0, t_e]$ for an unseen subject's $C_R[t = t_s, t_e]$. Both techniques make use of a population of subjects for which the full $C_R[t = 0, t_e]$ was measured.

The first method, referred to as the *scaled mean C_R* method and proposed by Scott et al.,⁹ scales the population average reference region curve, $\bar{C}_{R[t=0, t_e]}^{pop}$, as

$$C_{R[t=0, t_e]} \approx \alpha \bar{C}_{R[t=0, t_e]}^{pop} \quad (5)$$

where α is a subject specific scaling factor determined through a least squares fit of $\bar{C}_{R[t=t_s, t_e]}^{pop}$ to $C_{R[t=t_s, t_e]}$. This results in an individual estimate of $C_{R[t=0, t_e]}$ to be used in the RT-SRTM.

The second method employs statistical shape modelling to build a model of the variation in C_R within the population of subjects.¹⁸ This requires principal component analysis (PCA) of a set of subjects to determine the M components, $U = [\vec{u}_1, \dots, \vec{u}_M]^T$ where $\vec{u}_i = [u_1, \dots, u_{frames}]$, and is therefore referred to as the *PCA C_R* method.

The $C_R[t = 0, t_e]$ of each subject in the set can be expressed as the mean population reference curve, $\bar{C}_{R[t=0, t_e]}^{pop}$, plus a linear combination of the weighted principal components, where the weight of the i th mode, \vec{u}_i , is w_i . A subset, L where $L < M$, of the components which describe the majority of the variation are selected. An unseen reference region curve $C_{R[t=t_s, t_e]}$ can then be fitted by adjusting the weights, as per equation (6). The same weights and modes can then be used with $\bar{C}_{R[t=0, t_e]}^{pop}$ to generate $C_{R[t=0, t_e]}$. See Supplementary Materials for more details

$$C_{R[t=t_s, t_e]} \approx \bar{C}_{R[t=t_s, t_e]}^{pop} + \sum_{i=1}^L w_i \vec{u}_i \quad (6)$$

Fitting the SRTM with CBF-derived R_1 and extrapolated C_R . To apply the modifications to the SRTM with reduced

acquisition time, the operational equation in (1) is rewritten as in equation (7). This groups the measured parameter $C_T(t)$, with the derived $C_R(t)$ and derived R_1 into a dummy variable, $C_T^\ddagger(t)$, as they are determined prior to fitting

$$C_T^\ddagger(t) = C_T(t) - R_1 C_R(t) = \phi C_R(t) \otimes e^{-\theta t}$$

where

$$\phi = k_2 - R_1 \frac{k_2}{(1 + BP_{ND})}, \theta = \frac{k_2}{(1 + BP_{ND})} \quad (7)$$

To solve equation (7) for a reduced acquisition time where $t = t_s, t_e$, the basis function approach¹⁵ is used to pre-calculate the convolution term using the extrapolated $C_R(t = 0, t_e)$ with a range of biologically plausible values for θ . A least squares fit to the pre-determined data, $C_T^\ddagger(t = t_s, t_e)$, is performed for each θ to estimate ϕ , and the instance of θ which yields the lowest sum of squares difference is selected. BP_{ND} and k_2 are then derived from ϕ , θ and the CBF-derived R_1 . For more details, including the pseudo-code, see Supplementary Materials.

Data

Imaging data were collected from 60 cognitively normal subjects participating in Insight 46, a neuroimaging sub-study of the Medical Research Council National Survey of Health and Development,¹⁹ and 4 subjects from a study of young onset Alzheimer's Disease (YOAD) with an intermediate or high certainty diagnosis.²⁰ These studies were conducted in line with the principles of the Declaration of Helsinki. For Insight 46, ethical approval was obtained from the National Research Ethics Service (ref 14/LO/1173), and for YOAD, approval was obtained from the London Queen Square Ethics Committee (ref 15/LO/1412). Written informed consent was obtained from all participants.

All subjects underwent 60 min of simultaneous amyloid PET and multi-modal MR imaging on a Siemens Biograph mMR PET/MR scanner. Of the 64 subjects used for analysis, mean age 69.6 years (range 61.7–70.5 years), 45 had both PET and ASL data, and for 19 the ASL data were missing, either due to repetition of other scans (4) or imaging artefacts (15).

The subjects were divided into 2 sets; an optimisation set containing 39 subjects, and a testing set containing the remaining 25 subjects, see Figure 1. The clinically diagnosed YOAD subjects were evenly split between the two sets, as were amyloid positive ($a\beta^+$) subjects from Insight 46. Amyloid positivity was defined using mean cortical grey matter SUVR with a whole cerebellum reference region, see Supplementary Materials for details.




Figure 1. Flow chart describing data division between optimisation and testing sets, with the number of subjects defined as amyloid positive ($a\beta^+$) using SUVR with a whole cerebellum reference region.

Within the optimisation set, the 20 subjects with PET and ASL data were used to derive the relationship between PET- R_1 and ASL-CBF. The whole optimisation set was used to optimise the extrapolation of C_R and the acquisition timing window using leave-one-out cross validation. Finally, the relationship between PET- R_1 and ASL-CBF and the optimised C_R method from the optimisation set was used to apply the RT-SRTM to the 25 testing set subjects, see Supplementary Materials.

CBF estimation from ASL MRI

CBF was estimated from a pseudo-continuous ASL (pCASL) acquisition with the following parameters: 3D GRASE readout²¹ with 36 partitions and a reconstructed voxel size of $1.88 \times 1.88 \times 4$ mm, TE/TR=20.3/4000 ms, 4-shot with turbo-factor/EPI-factor=14/28, bandwidth 2298 Hz/pixel; 10 control-label pairs were acquired with a pulse duration (τ) and post labelling delay (PLD) both equal to 1800 ms. Acquisition time was 5 min 20 s ($t = 55, 60$). CBF maps were computed with equation (8)²²

$$CBF = \frac{6000\lambda S}{2\alpha S_0 T1_{blood}} \frac{e^{\frac{PLD}{T1_{blood}}}}{1 - e^{-\tau/T1_{blood}}} \left[\frac{ml}{100g} / min \right] \quad (8)$$

with 0.9 ml/g for the plasma/tissue partition coefficient (λ), a blood T1 of 1650 ms ($T1_{blood}$), and a labelling efficiency of 0.85 (α) as recommended in the ASL consensus paper.²³ S is the signal difference between the control and label images, S_0 maps were estimated by fitting saturation recovery images acquired with the same sequence at three different saturation times (1,2,4 s) using NiftyFit.²⁴

Dynamic PET acquisition and reconstruction

List mode PET data were acquired for 60 min following intravenous injection of [^{18}F]-florbetapir, which targets amyloid- β . For PET image reconstruction, simultaneously acquired structural T1- and T2-weighted MR images were used to synthesise CT data and calculate the attenuation map (μ -map),²⁵ as validated in Ladefoged et al.²⁶ The μ -map was propagated into PET space by registering the T1-weighted images to a full 60-min non-attenuation-corrected reconstructed PET image.

Dynamic PET data were binned into 31 time frames ($15\text{s} \times 4, 30\text{s} \times 8, 60\text{s} \times 9, 180\text{s} \times 2, 300\text{s} \times 8$), and reconstructed into $2 \times 2 \times 2$ mm voxels using the open source NiftyPET package.²⁷ An ordered subset expectation maximisation (OSEM) algorithm was used with 4 iterations, 14 subsets, and a 2 mm Gaussian filter, accounting for dead-time, attenuation, scatter, randomness and normalisation.

Regional analysis

T1-weighted MR images were parcellated into 17 regions: accumbens, amygdala, brainstem, caudate, cerebellum (white and grey separately), hippocampus, cerebral white matter, pallidum, putamen, thalamus and six cortical grey matter regions, with left and right hemispheres combined,²⁸ 16 regions were used for analysis, excluding the reference region.

Analysis was performed in native space such that the T1-weighted MR image was rigidly registered to both ASL (saturation recovery image target) and PET (μ -map transformation) space, and the transformation was propagated to the parcellation.²⁹

Statistical analysis

To compare different techniques with the gold standard, mean square error ($MSE = \frac{1}{n} \sum_{i=1}^n (Y_i - Y_i^*)^2$) and mean error ($MSE = \frac{1}{n} \sum_{i=1}^n (Y_i - Y_i^*)$) were used, where n is the number of estimates, Y_i^* is the gold standard estimate or measured value and Y_i is the estimate being evaluated. To compare different techniques, statistical significance was tested using paired, two-tailed Wilcoxon signed-rank test for MSE (as the data are not normally distributed), and paired two-tailed t -tests for ME.

Results

Relationship between ASL-CBF and PET- R_1

Figure 2(a) shows the relationship between PET- R_1 and ASL-CBF across the 16 regions for 20 optimisation set subjects. Linear regression shows a statistically




Figure 2. Correlation of PET- R_1 with ASL-CBF for 20 optimisation set subjects where the regression was calculated and applied to the ASL-CBF data to show the residual error in the fit. (a) PET- R_1 against ASL-CBF with single linear regression (black dashed line), (b) Residual normality plot for single linear regression R_1 estimation, inset: histogram of residuals, (c) PET- R_1 against ASL-CBF with multi-linear regression (black dashed lines), (d) Residual normality plot for multi-linear regression R_1 estimation, inset: histogram of residuals.

significant correlation between the two parameters ($\rho=0.349$, $p < 0.001$); however, there is some variability which is not explained by this linear model. Noise and artefacts in the ASL data are considered to be the main causes of the variability; however, violations of the model assumptions may also contribute.

Residual analysis was performed to determine whether a non-linear model could be fitted to the data, as suggested by equation (2). The normality plot for the residual error in Figure 2(a) is shown in Figure 2(b). This demonstrates that the residuals follow an approximately normal distribution, which supports the use of a linear model. However, there is some deviation from normality at the extremes, which is illustrated by the histogram inset in Figure 2(b). This shows that there are some outlying positive residuals which skew the distribution.

To quantify the regional and subject effects, multi-linear analysis was also performed. Multi-linear regression using the region name as a covariate was found to explain much of the variation seen in the single linear regression and gives an R^2 value of 0.650 (adjusted

$R^2=0.613$). Figure 2(d) shows that the residual error using multi-linear regression is lower and more normally distributed than single linear regression.

Figure 2(c) shows the multi-linear regression by region which demonstrates the variability in slope and intercept between regions. These differences can be attributed to two main causes: regional differences in bolus transit times meaning that the ASL label image is acquired before the bolus reaches the tissue, and regional differences in tracer extraction. Acquiring ASL data with multiple post-labelling delay times can be used to reduce some of this variability and would be particularly helpful when transit time changes are caused by pathology which cannot be modelled. However, this multi-linear regression using region as a covariate provides a good model for the data used here.

To quantify the subject specific component of the relationship between normalised ASL-CBF and PET- R_1 which cannot be modelled in a new set of subjects, multi-linear regression with the subject as a covariate was performed. This gave an R^2 value of 0.436 (adjusted $R^2=0.358$) indicating that there is some

variation between subjects, but that this accounts for less of the variation than the variation between regions. Finally, multi-linear regression using both region and subject as covariates yielded an R^2 value of 0.862 (adjusted $R^2 = 0.824$), showing that most of the variation can be explained by these two parameters.

There is insufficient evidence that the data used here could support a more complex non-linear model, which supports the linear Renkin–Crone model in equation (2) under the assumption that $\frac{PS}{f} \geq 3$. Since the multi-linear regression using region as a covariate is better able to describe the variation in the data, this model was selected for use when applying the RT-SRTM in the subsequent sections.

Extrapolation of PET reference region, C_R

Optimisation of PCA C_R method. Table 1 shows the percentage of the variation described as the number of components are increased for the population of 39 subjects, $C_{R[0,60]}^{pop}$. This demonstrates that six principal components are required to describe 99.9% of the variation within the data; therefore, a maximum of six components are used in the optimisation ($L \leq 6$).

Figure 3 shows the MSE in the fit of $C_{R[t=30,60]}$ using leave-one-out cross validation and averaged across subjects. This demonstrates that constraining the upper and lower bounds of the weights reduces the error when fitting to data with missing timepoints. The number of components used (L) has less of an influence on the error, and overall the combinations of components and weight bounds with the lowest error are $L = 6$ with either ± 0.5 or 1 times the standard deviation for the bounds, or $L = 3$ with ± 1 times the standard deviation for the bounds. These three combinations give a similar MSE for $t = 30, 60$; however, $L = 6$ with 1 times the standard deviation for the bounds was found to perform consistently better across different timing windows, and therefore this was used for comparison with the *scaled mean C_R* method in the following sections.

Comparison of PCA C_R and scaled mean C_R methods. The boxplot in Figure 4(a), which summarises across all subjects, shows that the *PCA C_R* method performs better for $t = 0, 30$ and $t = 20, 50$; however, the difference in MSE did not reach statistical significance at any timepoint ($p \geq 0.241$). The influence of this error on the estimation of BP_{ND} at different acquisition windows is assessed in the next section.

Optimisation of data acquisition window

The MSE and ME in the estimation of BP_{ND} using different data acquisition windows are shown in Table 2.

Table 1. The percentage of the variation explained using increasing number of principal components following PCA on the $C_{R[t=0,60]}$ of 39 optimisation set subjects.

Number of components (L)	Variation described (%)
1	76.4
2	95.0
3	97.8
4	99.1
5	99.6
6	99.9




Figure 3. MSE in the fit of $C_{R[t=30,60]}$ using the *PCA C_R* method when optimising the number of components used and the upper and lower bounds for the weights using leave-one-out analysis on 39 optimisation set subjects.

Extrapolation of C_R is not strictly necessary for $t = 0, 30$ as it starts from injection; thus, the basis functions can be generated using the measured data alone. However, this leads to a higher MSE of 0.1960 due to higher errors in the computation of the convolution, and therefore the results given always extrapolate C_R for $t = 0, 30$.

In Table 2, the true C_R column uses the full measured $C_R(t = 0, 60)$, therefore errors are introduced purely due to the limited number of datapoints available. When the later frames are omitted and only $t = 0, 30$ min of data are acquired, large errors are introduced as there is little information about the late phase which contains the signal relating to target binding. As the time window is shifted later, the MSE and ME are reduced.




Figure 4. Box-plots calculated using leave-one-out cross validation in 39 optimisation set subjects. (a) ME in the PCA C_R method and scaled mean C_R method compared to measured C_R , (b) Error in BP_{ND} estimates across different timing windows using different estimates of C_R .

However, the results in Table 2 also show that there is little to be gained by including data acquired more than 50 min post injection as the error increases. This is because the signal has plateaued by this point

so, for a fixed 30-minute window, a better fit can be obtained by including some of the earlier data where the tracer concentration changes more rapidly over time. This is further illustrated in Figure 4(b), which

Table 2. MSE and ME between gold standard BP_{ND}^* and BP_{ND} at different 30-min acquisition windows averaged across 16 regions and 39 optimisation set subjects.

Time window ($t= t_s, t_e$)						True C_R		PCA C_R		Mean C_R	
0,10	10,20	20,30	30,40	40,50	50,60	MSE	ME	MSE	ME	MSE	ME
●	●	●	○	○	○	0.0089	0.0303	0.0085	0.0299	0.0085	0.0299
○	●	●	●	○	○	0.0035	0.0202	0.0036	0.0202	0.0035	0.0211
○	○	●	●	●	○	0.0008	0.0050	0.0010	0.0041	0.0012	0.0088
○	○	○	●	●	●	0.0030	-0.0084	0.0032	-0.0090	0.0034	-0.0050

Note: True C_R uses the true reference region curve, PCA C_R and mean C_R extrapolate the reference region curve using the PCA C_R and scaled mean C_R methods, respectively. All methods used the gold standard R_1^* .

shows the smallest distribution of errors in BP_{ND} at $t=20,50$.

For the two techniques which extrapolate C_R from the available time window, additional variability is introduced into the BP_{ND} estimates due to errors in the extrapolation, which is reflected by the higher MSE in Table 2. For both the PCA C_R and the scaled mean C_R method, the early phase of the data becomes more important, as much of the variation between the C_R of subjects is contained in these frames. This can be seen in Figure 4(a), as for $t=0,30$ the error in C_R estimation is at a minimum and increases as the acquisition window shifts later. When the early frames are included, the error in BP_{ND} is very similar to using the true C_R , whereas when only the late frames are used, the error in BP_{ND} for the extrapolation methods increases relative to the true C_R , Figure 4(b). Table 2 shows that the optimal timing window for this technique is $t=20,50$ min post injection as it yields the lowest MSE and ME.

The PCA C_R method produces a consistently lower MSE which was statistically significantly lower than that obtained using the scaled mean C_R method for $t=20,50$ ($p=0.002$). This is due to the increased flexibility in this method which allows it to better describe the variation in unseen C_R shapes. The PCA C_R method also produces BP_{ND} estimates with lower bias at $t=20,50$, as demonstrated by the median lines in Figure 4(b) and the ME in Table 2 ($p<0.001$).

Due to the lower MSE and ME, the PCA C_R method with the $t=20,50$ min timing window was selected for the full implementation of the RT-SRTM in subsequent sections.

Comparison of proposed RT-SRTM with gold standard

Figure 5(a) shows BP_{ND} , estimated using the RT-SRTM with $t=20,50$ min of data plotted against the gold standard BP_{ND}^* . Linear regression of the data shows that the RT-SRTM method offers a good

approximation of the gold standard as it closely follows the line of identity (dashed), which is within the 95% confidence interval (CI) of the regression (shaded). The linear correlation between the two estimates was tested using the Pearson correlation coefficient which demonstrated a high, statistically significant result ($\rho=0.896$, $p<0.001$, 95% CI [0.875, 0.914]).

To determine the influence of CBF derived R_1 errors on BP_{ND} , sensitivity analysis was performed as described in the supplementary materials. Briefly, PET time activity curves were simulated using the realistic parameters with a range of noise values³⁰ and fitted using the optimised RT-SRTM with a fixed R_1 error. It was found that, for regional analysis where noise $<3.4\%$, the mean absolute error was smaller than the blood flow component found in SUVR in Cselenyi et al.⁴ However, if the methodology were to be extended to voxel-wise analysis, a lower R_1 error would be required due to the increased noise in the PET data which increases the uncertainty in the model fit.

Comparison of proposed RT-SRTM with SUVR - 1

To ensure a fair comparison between RT-SRTM and SUVR, $SUVR-1$ was calculated at five 10-minute acquisition windows, starting at $t=30$, to cover the recommended time range and compared to the gold standard BP_{ND} , see supplementary materials. The optimal timing window with the lowest bias and error was found to be $t=50,60$ minutes post injection, which is in concordance with the literature,⁴ hence $t=50,60$ was used for comparison.

Figure 5(b) shows the amyloid burden estimates generated for $SUVR-1$ ($t=50,60$ minutes). Whilst the correlation between $SUVR-1$ and BP_{ND}^* is evident, a positive bias is shown as $SUVR-1$ overestimates the binding potential at higher values. This is due to the fact that the target and reference tissue concentrations reach equilibrium with blood plasma at different points depending on tracer binding, as has been




Figure 5. Estimated amyloid burden against the gold standard value calculated using full PET time series for 25 testing set subjects using 4 different methods: (a) RT-SRTM where $t = 20, 50$ min (ASL-derived R_1), (b) $SUVR - 1$ where $t = 50, 60$ min, (c) SRTM where $t = 0, 30$ min (PET data only, no C_R extrapolation), (d) RT-SRTM where $t = 20, 50$ min (PET data only, extrapolated C_R). The grey-shaded region covers the 95% confidence interval in the regression.

explored in detail in the literature.³¹ The ME quantifies the bias between the estimates and the gold standard which is 0.1038 for $SUVR - 1$, indicative of the systematic overestimation, compared to 0.0079 for the RT-SRTM method ($p < 0.001$). The RT-SRTM method also has a lower MSE (0.0066 compared to 0.0235 for $SUVR - 1$, $p < 0.001$), showing that overall this technique is more accurate at estimating BP_{ND}^* than the simplified technique.

This overestimation in $SUVR - 1$ is likely to be a combination of a linear systematic error in the estimation, as well as the influence of blood flow. Systematic error could result from estimating $SUVR - 1$ when not at steady-state, and could potentially be accounted for using a population correction factor.

To determine the influence of blood flow on the estimation of target density, the correlation between estimated target density and tracer delivery was calculated,

as in Cselényi and Farde⁴ Spearman's correlation (ρ) between R_1^* and the estimates was calculated, as the relationship is in theory non-linear. For the gold standard BP_{ND}^* and BP_{ND} using RT-SRTM, there was no significant correlation with R_1^* ($p=0.336$ and 0.106 respectively). However, for $SUVR - 1$, there was a significant negative correlation ($\rho=-0.226$, $p < 0.001$), which suggests that the proposed RT-SRTM method may be more robust to changes in blood flow than $SUVR - 1$.

Comparison of the proposed RT-SRTM with short acquisition time PET

Pharmacokinetic modelling can be applied to reduced acquisition time PET data without incorporating ASL data in several ways, e.g.: (i) fitting the first 30 min of PET data only using the standard SRTM in equation (1), (ii) extrapolating C_R as in RT-SRTM, but R_1 is estimated from the PET data.

For the first method, (i), Figure 5(c) compares the estimation of BP_{ND} using the PET data for $t=0,30$ min to the gold standard. It is evident that the absence of late-phase data leads to a high error in the estimate, which is significantly higher than using the RT-SRTM (MSE = 0.0813, $p < 0.001$; ME = 0.0569, $p < 0.001$).

Using the second method, the estimation of BP_{ND} using $t=20,50$ min of PET data and extrapolating using the PCA C_R method, Figure 5(d) shows a significantly lower MSE compared to using the first 30 min (MSE = 0.0121, $p < 0.001$). The timing window $t=20,50$ was selected by calculating the MSE for all the timing windows used in Table 2 and $t=20,50$ yielded the lowest value. This method also outperforms $SUVR - 1$ with a lower MSE ($p < 0.001$) and ME ($p < 0.001$); however, it is significantly correlated with the gold standard R_1^* ($p=0.004$).

Comparison of the PET only method with the proposed RT-SRTM including ASL derived R_1 estimates shows that the additional CBF information improves the estimate of BP_{ND} , yielding a significantly lower MSE ($p=0.028$), ME ($p < 0.001$) and variance (two-tailed F-test $p < 0.001$). This can be seen in Figure 5(a) where the points are more tightly clustered around the line of identity when using the proposed RT-SRTM compared to Figure 5(d) using PET data only.

Discussion

In this paper, we have presented an improved framework for quantitative PET analysis with significantly reduced acquisition time, exploiting blood flow information from simultaneously acquired ASL MRI data.

We have demonstrated that the relationship between the blood flow and tracer delivery for [¹⁸F]-florbetapir,

which is described by the Renkin-Crone model, may be approximated as regionally linear and used to convert ASL relative CBF values into pseudo- R_1 estimates. We have also evaluated a new technique for extrapolating the reference region time activity curve, C_R , using PCA which introduces a lower error than the method used by Scott et al.,⁹ where the mean population is scaled. The timing of the PET acquisition was then optimised, and found to be $t=20,50$ min post injection.

When the RT-SRTM estimates of BP_{ND} using $t=20,50$ min of PET data and ASL derived R_1 were compared to the gold standard using the full 60 min of PET data, a strong linear correlation was found. This demonstrates that the RT-SRTM with a 30-min acquisition could potentially be used as a proxy for the full 60-min acquisition for this tracer and subject group.

By comparison, the simplified measure, $SUVR - 1$, using 10 min of data showed a strong positive bias in the target density estimation, and the results were correlated with the delivery of the tracer as determined by the gold standard R_1 estimates. This implies that, in addition to systematic error within the $SUVR - 1$ estimates, there is also a bias introduced due to local differences in blood flow. This may confound longitudinal studies, as blood flow may change over time, over the progression of disease, or due to disease modifying interventions. Conversely, the RT-SRTM estimates of target density were not correlated with R_1 , suggesting that this technique may be robust to changes in blood flow and could be a suitable alternative for longitudinal studies. However, this needs to be validated in a longitudinal dataset.

$SUVR - 1$ estimation at different timing windows showed that $t=50,60$ min gave the best estimation of BP_{ND} . Since $SUVR - 1$ appears to have plateaued by this point, it is unlikely that the estimation can be improved by acquiring data at a later timepoint.

This paper focused on the optimisation of a 30-min PET/MR acquisition. Simultaneous acquisition ensures that the CBF measured by ASL represents the flow at tracer injection, avoiding errors introduced by physiological flow changes throughout the day.² This assumes negligible change in blood flow between the tracer injection and the end of the scan. This can be controlled through measures used for routine clinical PET scans, such as keeping the patient lying down in an uptake room from injection to scan start. The influence of auditory stimulation, which would be present during the ASL scan but not during tracer injection, on CBF should also be considered, and if necessary the conditions in the scanner should be emulated in the uptake bay. If conditions could be adequately controlled, the technique could be extended to separate PET and MRI acquisitions. However, this would be heavily dependent on the scheduling of the scans and the acquisition time

saved is reduced compared to the simultaneous PET/MRI method.

A 30-min acquisition was selected to accommodate a typical MRI neuroimaging session, while still greatly increasing patient throughput and comfort. This could be further reduced depending on the MRI data acquired, where the minimum time is determined by the acquisition of the ASL data and the images required for attenuation correction of the PET data. In this case, using the *PCA C_R* method with fewer principal components should be considered to avoid an under-determined problem where there are more parameters to fit than datapoints available.

The ASL data used in this study were acquired for just 5.5 min over 50 min into the scan with no motion correction and no patient restraint. For this reason, approximately 30% of the ASL-CBF maps failed quality control checks, largely due to motion-induced artefacts. This represents a challenging dataset which could be significantly improved by increasing the number of acquisitions and motion correction. However, the fact that the RT-SRTM worked so well on this dataset indicates that it could be a clinically useful tool. It is worth noting that the data acquired from the four clinically diagnosed YOAD subjects all passed the quality control checks.

The limited time available within the protocol for the ASL acquisition also meant that a single delay time between blood tagging and image acquisition was used. This yields errors in CBF estimation due to different bolus transit times for different brain regions, either due to normal physiology or pathological changes. A multi-delay time ASL acquisition would make the methodology more robust as the transit time is parameterised within the model and this will be evaluated in future work.

The RT-SRTM was here applied to an amyloid- β tracer; however, the methodology could potentially be used for any tracer which can be described by the SRTM, and which has a sufficiently high extraction fraction, such as [¹⁸F]-flutemetamol, another amyloid- β tracer, or tau (τ) tracers.³² The kinetics of these tracers are slower than those of [¹⁸F]-florbetapir, and as such require longer dynamic acquisitions. Here, the RT-SRTM could potentially offer a greater reduction in acquisition time, and in future work, we intend a comparison with the dual time-window protocol, another acquisition time reduction method used on such tracers, where early and late PET data are acquired with a break in-between.³³ Furthermore, our approach could be broadened to other kinetic models which have a tracer delivery parameter that can be approximated using CBF from ASL. Reference region curve extrapolation could also be used in reference

Logan analysis,³⁴ as an alternative to a previously proposed reduced acquisition time method which cannot account for blood flow changes.³⁵

The main limitation of this study is that the optimisation of the RT-SRTM has been performed on cross-sectional dynamic scans of mostly healthy volunteers. The introduction of subjects with disease may increase the variability in C_R between subjects. However, some variability already exists in the dataset used as the healthy subjects undergo normal ageing and we include four clinically diagnosed subjects, which the *PCA C_R* method can handle. Provided that the dataset used to build the model for the *PCA C_R* method includes diseased subjects, this variability can also be accounted for.

In future work, this technique will be validated on longitudinal data including symptomatic patients, to further investigate its robustness to disease progression and local changes in blood flow. The linear relationship found between R_1 and relative CBF will require verification on such datasets to ensure that the assumption of $\frac{PS}{F} \geq 3$ still holds in symptomatic subjects.

Another limitation within the proposed technique is that tracer delivery is estimated directly from ASL-CBF using a region-dependent linear relationship. This works well for regional data as artefacts can be averaged out; however, this is not possible for voxel-wise analysis where errors will propagate through to the R_1 estimate. A more robust methodology which propagates database R_1 values into the subject space based on local image similarity has been proposed³⁶ and will be investigated in the future. This would facilitate voxel-wise analysis for quantitative parametric imaging within a clinically feasible time frame.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the EPSRC UCL Centre for Doctoral Training in Medical Imaging (EP/L016478/1), UCL Leonard Wolfson Experimental Neurology Centre (PR/ylr/18575), EPSRC (EP/H046410/1, EP/J020990/1, EP/K005278), MRC (MR/J01107X/1), NIHR UCLH Biomedical Research Centre (Inc. High Impact Initiative, BW.mn.BRC10269), and the Alzheimer's Society (AS-PG-15-025). The Tesla K20 used for the PET reconstruction was donated by the NVIDIA Corporation. Insight 1946 receives funding from Alzheimer's Research UK (ARUKPG2014-1946, ARUKPG2014-1946), MRC Dementia Platform UK (CSUB19166), The Wolfson Foundation, and Brain Research Trust. The Florbetapir tracer was kindly supplied by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly. This work was partly supported by the Wellcome/EPSCRC Centre for Medical Engineering [WT 203148/Z/16/Z].

Acknowledgements

The 3D GRASE pCASL sequence used in this work was kindly provided by Dr Federico von Samson-Himmelstjerna and Professor Matthias Günther (Fraunhofer MEVIS, Bremen, Germany). We acknowledge Roger Gunn for providing help with the simplified reference tissue model and Kjell Erlandsson for the useful comments and discussion of the manuscript. We are grateful to the Insight 46 and YOAD participants for their involvement in this study.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Authors' contributions

CJS performed the analysis, data interpretation, and wrote and revised the manuscript. JJ, PJM and NB advised on PET data analysis, and AM, EDV and DLT advised on ASL analysis. JJ, AM, EDV and DLT contributed to manuscript structure. JJ, AM, EDV, DLT, AOC, PSJW, PJM, NB, DMC, JMS, BFH and SO contributed to study design, data acquisition and critically revised and approved the manuscript.

Supplementary material

Supplementary material for this paper can be found at the journal website: <http://journals.sagepub.com/home/jcb>

ORCID iD

Catherine J Scott  <http://orcid.org/0000-0003-0129-738X>

References

1. Benedictus MR, Leeuwis AE, Binnewijzend MAA, et al. Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer's disease. *Eur Radiol* 2017; 27: 1169–1175.
2. Parkes LM, Rashid W, Chard DT, et al. Normal cerebral perfusion measurements using arterial spin labeling: reproducibility, stability, and age and gender effects. *Magn Reson Med* 2004; 51: 736–743.
3. van Berckel BNM, Ossenkoppele R, Tolboom N, et al. Longitudinal amyloid imaging using 11C-PiB: methodological considerations. *J Nucl Med* 2013; 54: 1570–1576.
4. Cselényi Z and Farde L. Quantification of blood flow-dependent component in estimates of beta-amyloid load obtained using quasi-steady-state standardized uptake value ratio. *J Cereb Blood Flow Metab* 2015; 35: 1485–149.
5. Hsiao IT, Huang CC, Hsieh CJ, et al. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. *Eur J Nucl Med Mol Imag* 2012; 39: 613–620.
6. Chen YJ, Rosario BL, Mowrey W, et al. PiB relative delivery (R1) as a proxy of relative cerebral blood flow: quantitative evaluation using single session 15O-water and 11C-PiB PET. *J Nucl Med* 2015; 56: 1199–1205.
7. Fan AP, Jahanian H, Holdsworth SJ, et al. Comparison of cerebral blood flow measurement with [15O]-water positron emission tomography and arterial spin labeling magnetic resonance imaging: a systematic review. *J Cereb Blood Flow Metab* 2016; 36: 842–861.
8. Goetti R, Warnock G, Kuhn FP, et al. Quantitative cerebral perfusion imaging in children and young adults with moyamoya disease: comparison of arterial spin-labeling-MRI and H2[15O]-PET. *AJNR Am J Neuroradiol* 2014; 35: 1022–1028.
9. Scott CJ, Jiao J, Melbourne A, et al. ASL-incorporated pharmacokinetic modelling of PET data with reduced acquisition time: application to amyloid imaging. In: Ourselin S, Joskowicz L, Sabuncu MR, et al. (eds) *MICCAI 2016. LNCS*, vol. 9902, 2016, pp. 406–413. Springer, Cham. DOI: 10.1007/978-3-319-46726-9_47.
10. Lammertsma A and Hume S. Simplified reference tissue model for PET receptor studies. *Neuroimage* 1996; 158: 153–158.
11. Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer Disease using the radioligand 18F-AV-45 (Flobetapir F 18). *J Nucl Med* 2010; 51: 913–920.
12. Sojkova J, Goh J, Bilgel M, et al. Voxelwise relationships between distribution volume ratio and cerebral blood flow: implications for analysis of beta-amyloid images. *J Nucl Med* 2015; 56: 1042–1047.
13. Golla SSV, Verfaillie SCJ, Boellaard R, et al. Quantification of [18 F] florbetapir: a test – retest tracer kinetic modelling study. *J Cereb Blood Flow Metab*. Epub ahead of print 13 June 2018. DOI: 10.1177/0271678X18783628.
14. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. *Ann Neurol* 2004; 55: 306–319.
15. Gunn RN, Lammertsma AA, Hume SP, et al. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. *Neuroimage* 1997; 6: 279–287.
16. Renkin E. Transport of potassium-42 from blood to tissue in isolated mammalian skeletal muscles. *Am J Physiol* 1959; 197: 1205–1210.
17. Crone C. The permeability of capillaries in various organs as determined by use of the indicator diffusion method. *Acta Physiol Scand* 1963; 58: 292–305.
18. Cootes TF, Taylor CJ, Cooper DH, et al. Active shape models: their training and application. *Comp Vis Image Underst* 1995; 61: 38–59.
19. Lane CA, Parker TD, Cash DM, et al. Study protocol: Insight 46 – a neuroscience sub-study of the MRC National Survey of Health and Development. *BMC Neurol* 2017; 17: 75.
20. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011; 7: 263–269.

-
21. Günther M, Oshio K and Feinberg DA. Single-shot 3D imaging techniques improve arterial spin labeling perfusion measurements. *Magn Reson Med* 2005; 54: 491–498.
 22. Buxton RB, Frank LR, Wong EC, et al. A general kinetic model for quantitative perfusion imaging with arterial spin labeling. *Magn Reson Med* 1998; 40: 383–396.
 23. Alsop DC, Detre JA, Golay X, et al. Recommended implementation of arterial spin-labeled Perfusion mri for clinical applications: a consensus of the ISMRM Perfusion Study group and the European consortium for ASL in dementia. *Magn Reson Med* 2015; 73: 102–116.
 24. Melbourne A, Toussaint N, Owen D, et al. niftyfit: a software package for multi-parametric model-fitting of 4D magnetic resonance imaging data. *Neuroinformatics* 2016; 14: 319–337.
 25. Burgos N, Cardoso MJ, Thielemans K, et al. Multi-contrast attenuation map synthesis for PET/MR scanners: assessment on FDG and Florbetapir PET tracers. *Eur J Nucl Med Mol Imag* 2015; 42: 1447–1458.
 26. Ladefoged CN, Law I, Anazodo U, et al. A multi-centre evaluation of eleven clinically feasible brain PET/MRI attenuation correction techniques using a large cohort of patients. *Neuroimage* 2017; 147: 346–359.
 27. Markiewicz PJ, Ehrhardt MJ, Erlandsson K, et al. NiftyPET: a high-throughput software platform for high quantitative accuracy and precision PET imaging and analysis. *Neuroinformatics* 2018; 16: 95–115.
 28. Cardoso MJ, Modat M, Wolz R, et al. Geodesic information flows: spatially-variant graphs and their application to segmentation and fusion. *IEEE Trans Med Imag* 2015; 34: 1976–1988.
 29. Modat M, Cash DM, Daga P, et al. Global image registration using a symmetric block-matching approach. *J Med Imag* 2014; 1: 024003.
 30. Ichise M, Liow J-S, Lu J-Q, et al. Linearized reference tissue parametric imaging methods: application to 11C-DASB positron emission tomography studies of the serotonin transporter in human brain. *J Cereb Blood Flow Metab* 2003; 23: 1096–1112.
 31. Slifstein M. Revisiting an old issue: the discrepancy between tissue ratio-derived binding parameters and kinetic modeling-derived parameters after a bolus of the serotonin transporter radioligand 123I-ADAM. *J Nucl Med* 2008; 49: 176–178.
 32. Baker SL, Lockhart SN, Price JC, et al. Reference tissue-based kinetic evaluation of 18F-AV-1451 in aging and dementia. *J Nucl Med* 2016; 57: 1–30.
 33. Bullich S, Barthel H, Koglin N, et al. Validation of non-invasive tracer kinetic analysis of 18 F-florbetaben PET using a dual-time-window acquisition protocol. *J Nucl Med* 2018; 59: 1104–1110.
 34. Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. *J Cereb Blood Flow Metab* 1996; 16: 834–840.
 35. Tantawy MN, Jones CK, Baldwin RM, et al. 18F-Fallypride dopamine D2 receptor studies using delayed microPET scans and a modified Logan plot. *Nucl Med Biol* 2009; 36: 931–940.
 36. Scott CJ, Jiao J, Cardoso MJ, et al. Short acquisition time PET quantification using MRI-based pharmacokinetic parameter synthesis. In: Descoteaux M, Maier-Hein L, Franz A, et al. (eds) *MICCAI 2017. LNCS*, vol. 10434, 2017, pp. 737–744. Springer, Cham. doi:https://doi.org/10.1007/978-3-319-66185-8_83.